Enveric Biosciences Raises $3.1 Million Through Warrant Exercise

Reuters12-12

<a href="https://laohu8.com/S/ENVB">Enveric Biosciences</a> Raises $3.1 Million Through Warrant Exercise

Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211133281) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590454557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 02:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590454557","market":"nz","top_or_hot":-1,"title":"Enveric Biosciences Raises $3.1 Million Through Warrant Exercise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> Raises $3.1 Million Through Warrant Exercise\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211133281) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enveric Biosciences Raises $3.1 Million Through Warrant Exercise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnveric Biosciences Raises $3.1 Million Through Warrant Exercise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 02:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> Raises $3.1 Million Through Warrant Exercise\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211133281) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL9J0WzF:1","article_id":"2590454557","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590454557","pubTimestamp":1765478598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ENVB":"Enveric Biosciences"},"translate_title":"Enveric Biosciences通过行使认股权证筹集310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENVB":0.9},"content_text":"Enveric Biosciences Raises $3.1 Million Through Warrant Exercise\n    \n\n        Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211133281) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590454557","isCrawlerRequest":true}